Worth Venture Partners’s Avadel Pharmaceuticals AVDL Stock Holding History

Worth Venture Partners’s Portfolio AVDL Stock Details AVDL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-15,900	Closed	-$4K	–	154
2022 Q1	$4K	Buy	+15,900	New	+$109K	﹤0.01%	139
2020 Q3	–	Sell	-115,500	Closed	-$243K	–	119
2020 Q2	$243K	Buy	115,500 +56,700	+96%	+$500K	0.12%	87
2020 Q1	$103K	Buy	+58,800	New	+$452K	0.06%	88

Other funds holding AVDL

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

GJL

Gendell Jeffrey L $7.34B AUM 183.72% 1-Year Est. Return

CAC

Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return

BIP

Brandes Investment Partners La Jolla, California $14.1B AUM 25.52% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

Wealth Effects Boston, Massachusetts $282M AUM 62.81% 1-Year Est. Return

Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

PVI

Pura Vida Investments New York $14.9M AUM 38.76% 1-Year Est. Return

Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return

Worth Venture Partners's AVDL Position: Q2 2022 in Review

Worth Venture Partners sold out of Avadel Pharmaceuticals (AVDL) in Q2 2022, closing a stake of 15,900 shares — an estimated $109K sold.

Worth Venture Partners first reported a position in AVDL in Q1 2022 and held it in 1 quarter. The position peaked at $109K in Q1 2022. 82 funds tracked by Wall St. Rank hold AVDL as of Q2 2022.

Worth Venture Partners reported no remaining Avadel Pharmaceuticals position as of Q2 2022 after selling out during the quarter.
Worth Venture Partners sold 15,900 Avadel Pharmaceuticals shares in Q2 2022, an estimated $109K.
Worth Venture Partners first reported a position in Avadel Pharmaceuticals in Q1 2022 and held it in 1 quarter.
Worth Venture Partners's Avadel Pharmaceuticals position peaked at $109K in Q1 2022.
82 funds tracked by Wall St. Rank held Avadel Pharmaceuticals as of Q2 2022.

Based on Worth Venture Partners's 13F filing for Q2 2022, filed 15 Aug 2022.